Literature DB >> 32953348

Primary Uterine Rhabdomyosarcoma in a 54-Year-Old Postmenopausal Woman.

Ala M Aljehani1, Ahmed Abu-Zaid2, Osama Alomar3, Emad A Jabrah3, Abdulmohsen Alkushi4.   

Abstract

Rhabdomyosarcoma (RMS) is a malignant neoplasm that originates from undifferentiated myogenic progenitor cells. It is predominantly a pediatric disease, and its occurrence in adults is exceedingly rare. Adult primary RMS of gynecologic origin is an uncommon phenomenon, and the cervix is the most frequently involved site. The incidence of adult primary uterine RMS is extremely scarce. Herein, we present the case of primary uterine RMS in a 54-year-old Saudi postmenopausal woman who presented to clinic attention with a six-month history of abdominal pain and vaginal bleeding.
Copyright © 2020, Aljehani et al.

Entities:  

Keywords:  adult; myogenic progenitor cells; rhabdomyosarcoma; uterine

Year:  2020        PMID: 32953348      PMCID: PMC7497219          DOI: 10.7759/cureus.9841

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  11 in total

1.  Clinicopathologic analysis of patients with adult rhabdomyosarcoma.

Authors:  W G Hawkins; A Hoos; C R Antonescu; M J Urist; D H Leung; J S Gold; J M Woodruff; J J Lewis; M F Brennan
Journal:  Cancer       Date:  2001-02-15       Impact factor: 6.860

Review 2.  Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.

Authors:  R B Raney; J R Anderson; F G Barr; S S Donaldson; A S Pappo; S J Qualman; E S Wiener; H M Maurer; W M Crist
Journal:  J Pediatr Hematol Oncol       Date:  2001-05       Impact factor: 1.289

3.  Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: An analysis of 26,758 cases.

Authors:  Jorge R Toro; Lois B Travis; Hongyu Julian Wu; Kangmin Zhu; Christopher D M Fletcher; Susan S Devesa
Journal:  Int J Cancer       Date:  2006-12-15       Impact factor: 7.396

4.  What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract?

Authors:  C A Arndt; S S Donaldson; J R Anderson; R J Andrassy; F Laurie; M P Link; R B Raney; H M Maurer; W M Crist
Journal:  Cancer       Date:  2001-06-15       Impact factor: 6.860

5.  Adult rhabdomyosarcoma survival improved with treatment on multimodality protocols.

Authors:  Naamit Kurshan Gerber; Leonard H Wexler; Samuel Singer; Kaled M Alektiar; Mary Louise Keohan; Weiji Shi; Zhigang Zhang; Suzanne Wolden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-02-13       Impact factor: 7.038

6.  Uterine rhabdomyosarcoma in adults.

Authors:  Andre Pinto; Ryan M Kahn; Andrew E Rosenberg; Brian Slomovitz; Charles Matthew Quick; Michella K Whisman; Marilyn Huang
Journal:  Hum Pathol       Date:  2018-01-07       Impact factor: 3.466

7.  Clinicopathologic features of rhabdomyosarcoma of gynecologic origin in adults.

Authors:  Sarah E Ferguson; William Gerald; Richard R Barakat; Dennis S Chi; Robert A Soslow
Journal:  Am J Surg Pathol       Date:  2007-03       Impact factor: 6.394

8.  Adult rhabdomyosarcoma: outcome following multimodality treatment.

Authors:  Darren J Little; Matthew T Ballo; Gunar K Zagars; Peter W T Pisters; Shreyaskumar R Patel; Adel K El-Naggar; Adam S Garden; Robert S Benjamin
Journal:  Cancer       Date:  2002-07-15       Impact factor: 6.860

9.  Treatment of adult rhabdomyosarcoma.

Authors:  Christian M Ogilvie; Eileen A Crawford; Rachel L Slotcavage; Joseph J King; Richard D Lackman; Lee Hartner; Arthur P Staddon
Journal:  Am J Clin Oncol       Date:  2010-04       Impact factor: 2.339

Review 10.  Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution.

Authors:  Andrea Ferrari; Palma Dileo; Michela Casanova; Rossella Bertulli; Cristina Meazza; Lorenza Gandola; Pierina Navarria; Paola Collini; Alessandro Gronchi; Patrizia Olmi; Franca Fossati-Bellani; Paolo G Casali
Journal:  Cancer       Date:  2003-08-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.